The long-term effect of treatment with continuous positive airway pressure (CPAP) on erectile function was assessed in 60 patients with obstructive sleep apnea syndrome (OSAS). Severity of OSAS was evaluated by respiratory disturbance index (RDI) and minimal oxygen saturation (OxiMin). Severity of erectile dysfunction (ED) was assessed with the five question International Index of Erectile Function (IIEF-5) before and after CPAP treatment. Subjects were categorized into three groups on the basis of the change in IIEF-5 score: Group 1, no change (n ¼ 37); Group 2, improvement from 1075.65 to 19.175.7, Po0.01 (n ¼ 12); Group 3, worsening from 19.974.7 to 9.577.8, Po0.01 (n ¼ 11). Group 2 had significantly higher RDI and lower OxiMin than the other groups, and was also more compliant and satisfied with CPAP. Change in IIEF-5 with CPAP treatment was negatively correlated (Pearson coefficient) with OxiMin (r ¼ À0.374), and positively correlated with adherence to CPAP treatment (r ¼ 0.689). In conclusion, in selected patients, CPAP treatment for OSAS may by itself have a positive effect on erectile function by improving respiration during sleep. Predictors of erectile improvement include high RDI, low OxiMin, and CPAP compliance.
Introduction
Erectile dysfunction (ED) is defined by the NIH as the inability to achieve and maintain an erection sufficient to permit satisfactory sexual intercourse. 1 According to the 1995 estimates, over 152 million men worldwide had ED. The projected prevalence for 2025 is 322 million men with the largest increase expected in developing countries. 2 Obstructive sleep apnea syndrome (OSAS) is characterized by repetitive upper-airway occlusion (complete or partial), leading to a reduction in breathing rate or cessation of breathing. It is a common medical problem affecting up to 5% of middle-aged men. 3 Severity is assessed by two parameters: the respiratory disturbance index (RDI) , that is, the number of sleep apnea episodes during an hour; and the minimal oxygen saturation (OxiMin), measured by pulse oximetry, during the apnea episodes.
OSAS is associated with clinical complications such as: daytime somnolence, hypertension, ischemic heart disease, and increased risk of stroke. [4] [5] [6] [7] Their underlying pathological mechanisms include recurrent intermittent hypoxemia and increased sympathetic activity, primarily at the termination of the apneic events. 8, 9 In a previous study, 10 our group showed that OSAS is also associated with ED in a dose-related fashion. This association is very strong in patients with severe OSAS and weaker in patients with mild or moderate OSAS. Our findings are supported by several other studies reporting a high prevalence (30-68%) of ED in patients with OSAS. 11, 12 The treatment of OSAS by continuous positive airway pressure (CPAP) is well established. To the best of our knowledge, there are only two studies addressing the effect of CPAP on ED in patients with OSAS, 13, 14 both focused only on the acute, shortterm outcome. Karacan and Karatas, 13 reported that one-third of their subjects with ED showed improved results on nocturnal penile tumescence (NPT) after a single night of treatment with CPAP. Perimenis et al have used CPAP successfully for intercourse attempts as a primary outcome in their study, and they observed a 25% success rate in sexual attempts of men under CPAP therapy for 12 weeks.
The aim of the present study was to investigate the effect of long-term use of CPAP on ED in patients with OSAS.
Methods and materials

Patients
The study sample consisted of 103 consecutive patients with a diagnosis of OSAS by polysomnography who had been receiving CPAP treatment for at least 1 year. To assess the effect of CPAP alone on patients with OSAS and untreated ED with no related risk factors, we imposed relatively spacious exclusion criteria.
Exclusion criteria included: known ED treated with medication or intracavernous injections, hypertension (systolic blood pressure above 160 mmHg; diastolic blood pressure above 100 mmHg), diabetes mellitus, vascular diseases (deep vein thrombosis, peripheral vascular disease, Raynaud's disease, vasculitis syndromes, collagen diseases), and medications that could affect erection (eg, b blockers, H2 blockers). Data on RDI and OxMin prior to CPAP treatment were retrieved from their medical files. Data on ED were collected by a two-part self-reported questionnaire as follows: 
Data analysis
Subjects were categorized into three groups according to the change in IIEF-5 score in response to CPAP treatment:
1. No change in IIEF-5 score, or a change less than 74 points (n ¼ 37) 2. Improvement in IIEF-5 score of at least 4 points (n ¼ 12) 3. Worsening in IIEF-5 score of at least 4 points (n ¼ 11)
The RDI and OxiMin values and change in IIEF-5 score of patients from the three groups were compared using either ANOVA (for multiple variable comparisons) or t-test (for two-variable comparisons). For all comparisons, a P-value of less than 0.05 was considered statistically significant. The change in IIEF-5 score and sleep parameters (RDI, OxiMin) and CPAP compliance were correlated using Pearson's correlation coefficient.
Results
Questionnaires were sent to all 103 subjects who met inclusion criteria. Of the 103 patients, 60 (58%) completed the questionnaires. The median duration of CPAP treatment in the responders was 17 months (range 12-26 months). Patient characteristics, change in IIEF-5 score, compliance and satisfaction with CPAP treatment are shown in Table 1 . A total of 37 patients (62%) showed no change in IIEF-5 score after long-term CPAP treatment compared to baseline (Group 1); 12 patients (20%) had an improved score (Group 2); and 11 (18%) had a worse score (Group 3). Specifically, in Group 2, CPAP treatment significantly improved erectile function from an IIEF-5 score of 1075.65 (severe ED) to 19.175.7 (mild to moderate ED), Po0.01. In Group 3 however, IIEF-5 score worsened under CPAP treatment from 19.974.7 (mild to moderate ED) to 9.577.8 (severe ED), Po0.01. No statistically significant difference in age or body mass index was found among the three groups. Patients in Group 2 were significantly more satisfied with CPAP treatment than patients in groups 1or 3 (Po0.05). They were also significantly more compliant with treatment than patients in Group 3 (41.275.2 h/week of CPAP use vs There was a significant negative correlation between the change in IIEF-5 score with CPAP treatment and OxiMin values (r ¼ À0.374)). No correlation between the change in IIEF-5 score and RDI values was found (r ¼ 0.139).
Discussion
Penile erection is a neurovascular event modulated by psychological and hormonal factors. 15 On sexual stimulation, an increase in parasympathetic activity leads to a release of neurotransmitters from the cavernous nerve terminals and of relaxing factors from the endothelial cells of the penile vasculature.
This results in smooth muscle relaxation in the arteries and arterioles supplying the erectile tissue and a several-fold increase in blood flow to the penis. Penile venous outflow is simultaneously occluded by a venous compression mechanism, maintained by the penile tunica albuginea. Smooth muscle relaxation is brought about by the release of nitric oxide (NO) from both the endothelial cells and neural tissue supplying the corpora cavernosa. Thus, disturbances in the basic neurovascular event or the modulating factors that control this event (psychological or hormonal) may be responsible for ED.
There are several theories regarding the mechanism of ED in OSAS. The causes may be organic such as hypoxia-induced neural dysfunction, 16 blood vessel abnormalities caused by an increase in nocturnal blood pressure and sympathetic activation, 17 or hormonal, such as low level of androgens. 18 Psychological causes, on the other hand, may result from apnea-induced daytime somnolence 19 or depressed mood commonly seen in patients with apnea episodes. 20 Our findings of ED improvement with OSAS treatment are in concurrence with Karacan and Karatas', 13 which reported an improvement in a third of his patients with impaired NPT after a single night of CPAP treatment. Our findings are also in agreement with the recently published study by Perimenis et al. 14 The primary outcome in their The most important finding of our study is that in 20% of patient's, long-term CPAP treatment alone helped to alleviate ED. Interestingly, the same efficacy rates were reported by Perimenis et al.
14
When considering these results clinically, it becomes apparent that one of every five patients with OSAS and ED will respond to CPAP therapy. Owing to the apparently low response rate, the identification of clinically useful predictors of improvement is essential. In our study, the most significant predictors of improved erectile function under CPAP treatment were severe pretreatment OSAS, higher RDI value, and low oxygenation levels during apneic spells. The patients who benefited most were the ones who were most compliant and satisfied with CPAP therapy. The change in IIEF-5 score was negatively correlated with OxiMin values.
Another important finding was that in 18% of patients, erectile function worsened under CPAP treatment. These patients did not differ in any of the initial sleep parameters from the patients who showed no change. However, they were the least compliant and the least satisfied with CPAP treatment. We suggest that when patients struggle with CPAP during sleep, their sleep becomes increasingly fragmented, accompanied by an increase in sympathetic surges, resulting in a low-quality night time sleep and a daytime somnolence. 22 Thus, if ED deterioration appears while on CPAP treatment, clinicians should inquire about compliance and satisfaction with CPAP treatment. On the other hand, since we cannot prove suboptimal OSAS treatment in Group 3, IIEF-5 worsening may be ascribed to reasons other than CPAP use.
The negative correlation of the change in IIEF-5 scores with OxiMin values (r ¼ À0.374) was not accompanied by a significant correlation with RDI values. Researchers have long debated whether RDI or oxygenation better represents OSAS severity. Hypoxia has been shown to have a substantial effect on the endothelium, inducing production of various factors such as platelet-derived growth factor b, endothelin 1, and vascular endothelial growth factor. 23 It may also cause cavernosal fibrosis via transforming growth factor b (TGF-b). 24 Studies in rabbit and human cavernosal tissue found that hypoxia inhibited endothelial-mediated relaxation. 25 Therefore, the number of apneic spells may be less important than the degree of hypoxia during these spells. Although our study did not address causality, CPAP treatment has been shown to improve hypoxia, 26 increase plasma NO concentration, 27 decrease blood pressure and sympathetic overactivation, 28 and partially correct the central suppression of nocturnal testosterone in patients with OSAS. 29 All of which can ameliorate the suspected organic causes of ED in OSAS. A recent meta-analysis by Patel et al 30 found CPAP treatment to significantly improve subjective and objective measures of sleepiness in patients with OSAS. The patients with more severe apnea seemed to benefit more. This observation might explain why in our cohort, CPAP improved ED only in those with more severe OSAS. However, further study is needed to understand the physiological mechanism where by CPAP influences ED in patients with OSAS.
The vast majority (61%) of our cohort experienced no change in ED with CPAP treatment. In a recent review, Siroky and Azadzoi 31 stressed that reversal of vasculogenic ED is rarely possible. In addition, we used only CPAP to treat ED. Perimenis et al 14 compared the efficacy of sildenafil and CPAP in men with erectile dysfunction OSAS. In total, 30 were randomly treated for 12 weeks either with sildenafil 100 mg before intercourse (15 men) or CPAP during night time sleep (15 men). Under sildenafil, 97/180 (53.9%) of attempted intercourses were successful compared to 33/138 (23.9%) under CPAP. They concluded that a combination of the two therapeutic tools should be studied further. Although out of the scope of our study we believe that on-demand use of PGE-5 inhibitors may have a positive impact on the treatment response rate.
Our results must be viewed in light of the relatively low response rate to the IIEF-5 questionnaire (58%). Still, compared to a reported response rate of 50-80% in other questionnaire-based studies, the response rate in the present study is acceptable. To study the underlying cause of nonresponding, we have contacted 32 (74%) of the nonresponders and asked for the reason for nonresponding: 20 did not respond due to a language barrier and the others were not willing to respond to a questionnaire assessing their erectile function. Notwithstanding this potential limitation, we believe these results to be valid.
In conclusion, with the limitation of a retrospective, questionnaire-based design, this study is the first to report the long-term effect of CPAP treatment on erectile function in patients with OSAS. We have demonstrated that 20% of OSAS patients may improve their erectile function solely with CPAP treatment. The predictors of successful treatment are low Oximin values and satisfaction and compliance with CPAP use. However, there is a subset of patients in whom erectile function may deteriorate following CPAP treatment, characterized CPAP effect on erectile function D Margel et al by noncompliance to CPAP and relatively mild OSAS. Noncompliance with CPAP is a major obstacle in treating OSAS and a possible benefit of CPAP on erectile function may aid CPAP acceptance by the patients. Prospective controlled studies are needed to validate our findings.
